AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02530879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of anti-reflux medication and voice therapy
Description: Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
Study NCT02693600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligamentoplasty with partial trapeziectomy
Study NCT02693600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligamentoplasty with total trapeziectomy
Study NCT00964223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)
Description: Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
Study NCT00964223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Description: Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
Study NCT03110393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Description: Insert and intubation of an Ambu® AuraGain™ laryngeal mask
Study NCT03110393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intersurgical i-gel
Description: Insert and intubation of an Intersurgical i-gel®
Study NCT01340950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine-lamivudine-nevirapine
Description: 96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
Study NCT01340950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir-lamivudine-efavirenz
Description: 96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
Study NCT04975282 — intervention group
Intervention type: DEVICE
Intervention: Bottle feeding
Description: Bottle was used as an alternative oral feeding method for preterm infants.
Study NCT04975282 — intervention group
Intervention type: DEVICE
Intervention: Cup feeding
Description: Cup was used as an alternative oral feeding method for preterm infants.
Study NCT00085852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLVR
Description: 10 mL Hydrogel
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
Study NCT02390752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TURALIO(R)
Description: take oral drug daily for a 28 day cycle
Study NCT04856579 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Varicocelectomy
Description: Subinguinal varicocelectomy under general anesthesia and complete aseptic condition
Study NCT02458365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Choices: A Program for Healthy Nonviolent Relationships
Description: A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
Study NCT03266588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant
Description: 75 mg oral tablet
Study NCT04198129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Unasyn or Cleocin)
Description: Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
Study NCT04198129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Augmentin or Cleocin)
Description: the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
Study NCT03703492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (18F)FES
Description: 18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: \[18F\]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors
Study NCT03703492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Description: Gadolinium-based intravenous contrast agent used for the MRI portion of this study
Study NCT03809871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cardiometabolic biomarkers
Description: This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
Study NCT00796497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
Study NCT03288480 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PT-112
Description: This is a single arm study
Study NCT04547504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg once every 3 weeks for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or the Investigator's or the patient's decision to stop.
Study NCT02458365 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health In Motion
Description: A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
Study NCT00888030 — intervention group
Intervention type: OTHER
Intervention: there are no interventions currently listed for this study
Study NCT04547504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab and Chemotherapy drugs
Description: An induction therapy followed by a maintenance therapy.~4 induction cycles every 3 weeks associating, on the first day of each cycle:~* Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.~* Carboplatin AUC 6mg/mL/min, paclitaxel 200mg/m² and pembrolizumab 200mg for squamous NSCLC.~After the 4 induction cycles, a maintenance therapy will be possible for patients who are responding or stable:~* Non squamous NSCLC: pembrolizumab and pemetrexed combination or either drug as monotherapy.~* Squamous NSCLC: pembrolizumab monotherapy.~For pembrolizumab: treatment may be continued for a maximum of 35 cycles or until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.~For pemetrexed, treatment may be continued until disease progression, death, unacceptable toxicity, or following the Investigator's or the patient's decision to stop.
Study NCT01446822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)
Description: Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
Study NCT03241407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
Study NCT04198129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
Study NCT00122018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Study NCT03241407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triclosan/copolymer/fluoride toothpaste
Description: During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
Study NCT01825876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Oral administration
Study NCT01825876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral administration
Study NCT01825876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral administration
Study NCT04069104 — intervention group
Intervention type: BEHAVIORAL
Intervention: ABCD Information
Description: The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
Study NCT04069104 — intervention group
Intervention type: BEHAVIORAL
Intervention: UDS information
Description: The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
Study NCT04069104 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard (clinical) feedback
Description: Feedback on mole identification task provided by a dermatologist.
Study NCT04069104 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motivational feedback
Description: Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
Study NCT02642107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Elective neck irradiation
Description: Whole neck irradiation is given in the involved neck. Elective neck irradiation of Level II,III and Va lymph node area is given in the uninvolved neck, and Level IV and Vb lymph node area were not irradiated in the uninvolved neck.
Study NCT02642107 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole neck irradiation
Description: Whole neck irradiation is given regardless of the involved or uninvolved neck.
Study NCT05680311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: measurement of serum autotaxin serum level
Description: autotaxin expression
Study NCT05680311 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: measurement of serum autotaxin serum level
Description: autotaxin expression
Study NCT02104401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
Study NCT03608410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Internet based PRO questionnaires
Description: If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
Study NCT04089137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Change (+Change)
Description: This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault. This intervention targets alcohol use, sexual assault victimization risk, sexual assault perpetration, and bystander intervention and is tailored by gender and sexual orientation.
Study NCT02400827 — intervention group
Intervention type: OTHER
Intervention: malignant cells
Study NCT03302299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid 300 Mg ORAL TABLET
Description: The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
Study NCT03302299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine 25 Mg Oral Tablet
Description: All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
Study NCT02209454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enantyum® oral solution
Description: One dose of 25 mg DKP oral solution
Study NCT02209454 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Keral® tablet
Description: One dose of 25 mg DKP tablet
Study NCT00122018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenoldopam
Study NCT01345890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Description: sub motor threshold stimulation of mylohyoid muscles
Study NCT04052074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
Study NCT04052074 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: simulation with therapeutic education
Description: Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
Study NCT01386619 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD3-depleted/CD56+ selected natural killer cells collected from apheresis products
Description: NK DLI products containing >1 10e7 NK cells/kg bodyweight (BW) and \< 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
Study NCT04181554 — intervention group
Intervention type: OTHER
Intervention: Measurement of postural stability
Description: The postural stability will assess by using Biodex balance system.
Study NCT02815930 — intervention group
Intervention type: OTHER
Intervention: HCU Status
Description: Total healthcare expenditures in the top 5% of Ontarians
Study NCT01797952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus CD 2
Description: 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
Study NCT01797952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus CD 2
Description: 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
Study NCT01797952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo is a mix of sugars and salts used as excipients in the active formulation
Study NCT01797952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a mix of sugars and salts used as excipients in the active formulation
Study NCT02001480 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 12 lead Holter
Description: 12 lead Holter measurements will be performed for 7 days
Study NCT02001480 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CGM Continuous Glucose Monitoring
Description: CGM will be performed continously for 7 days
Study NCT00926653 — intervention group
Intervention type: DRUG
Intervention: Escitalopram
Description: 10 to 20 mg daily as part of another study in which participants are enrolled
Study NCT02983227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
Study NCT06404580 — intervention group
Intervention type: PROCEDURE
Intervention: R anastomosis
Description: R anastomosis
Study NCT04156308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) - Temp1
Description: A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
Study NCT01447979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable artificial pancreas system with Control-To-Range algorithms
Description: The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
Study NCT05322265 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic surgery for renal and adrenal diseases
Description: type of treatment for patients underwent to laparoscopic surgery for renal and adrenal diseases with intraoperative complications
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 1
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 2
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 3
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 4
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 5
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 6
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159 Single agent dose level 7
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 1
Description: Dose of PY159 and given in combination with pembrolizumab
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 2
Description: Dose of PY159 and given in combination with pembrolizumab
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 3
Description: Dose of PY159 and given in combination with pembrolizumab
Study NCT04156308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercises
Description: A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
Study NCT03676062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs applied three sessions per week, totally six week.
Study NCT01417312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsules with 160 mg Teavigo (at least 94% EGCG)
Description: Daily intake of 600 mg EGCG for 3 months
Study NCT01417312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of placebo capsules for 3 months
Study NCT01446822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)
Description: Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
Study NCT03030599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-258
Description: JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate
Study NCT03030599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial \[United States Pharmacopeia/ National Formulary\])
Study NCT04682431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PY159/Pembrolizumab Combination dose level 4
Description: Dose of PY159 and given in combination with pembrolizumab